Ledia F. Hernandez

Ledia F. Hernandez

Auto-generated profile, based on publicly available information

Ledia F. Hernandez

Movement Disorders Group, Neurosciences Department, CIMA, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Experimental Neurology
Verified
Journal Article
Closed access
JBJavier Blesa
Javier Blesa
ITInés Trigo-Damas
Inés Trigo-Damas
MDMichele Dileone
Michele Dileone
NRNatalia Lopez-Gonzalez del Rey
Natalia Lopez-Gonzalez del Rey
LHLedia F. Hernandez
Ledia F. Hernandez
JOJosé A. Obeso
José A. Obeso

16 October 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NLNuné Lemaire
Nuné Lemaire
LHLedia F. Hernandez
Ledia F. Hernandez
DHDan Hu
Dan Hu
YKYasuo Kubota
Yasuo Kubota
MHMark W. Howe
Mark W. Howe
AGAnn M. Graybiel
Ann M. Graybiel
A major physiologic sign in Parkinson disease is the occurrence of abnormal oscillations in cortico-basal ganglia circuits, which can be normalized by l -DOPA therapy. Under normal circumstances, oscillatory activity in these circuits is modulated as behaviors are learned and performed, but how dopamine depletion affects such modulation is not yet known. We here induced unilateral dopamine depletion in the sensorimotor striatum of rats and then recorded local field potential (LFP) activity in the dopamine-depleted region and its contralateral correspondent as we trained the rats on a conditional T-maze task. Unexpectedly, the dopamine depletion had little effect on oscillations recorded in the pretask baseline period. Instead, the depletion amplified oscillations across delta (∼3 Hz), theta (∼8 Hz), beta (∼13 Hz), and low-gamma (∼48 Hz) ranges selectively during task performance times when each frequency band was most strongly modulated, and only after extensive training had occurred. High-gamma activity (65–100 Hz), in contrast, was weakened independent of task time or learning stage. The depletion also increased spike-field coupling of fast-spiking interneurons to low-gamma oscillations. l -DOPA therapy normalized all of these effects except those at low gamma. Our findings suggest that the task-related and learning-related dynamics of LFP oscillations are the primary targets of dopamine depletion, resulting in overexpression of behaviorally relevant oscillations. l -DOPA normalizes these dynamics except at low-gamma, linked by spike-field coupling to fast-spiking interneurons, now known to undergo structural changes after dopamine depletion and to lack normalization of spike activity following l -DOPA therapy.

8 December 2017 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
Barbara PicconiBarbara Picconi
Barbara Picconi
LHLedia F. Hernández
Ledia F. Hernández
JOJose A. Obeso
Jose A. Obeso
PCPaolo Calabresi
Paolo Calabresi

6 July 2015 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
MMManuela Mellone
Manuela Mellone
JSJennifer Stanic
Jennifer Stanic
LHLedia F. Hernandez
Ledia F. Hernandez
EIElena Iglesias
Elena Iglesias
EZElisa Zianni
Elisa Zianni
FGFabrizio Gardoni
Fabrizio Gardoni
Levodopa-induced dyskinesias (LIDs) are major complications in the pharmacological management of Parkinson’s disease (PD). Abnormal glutamatergic transmission in the striatum is considered a key factor in the development of LIDs. This work aims at: (i) characterizing N-methyl-D-aspartate (NMDA) receptor GluN2A/GluN2B subunit ratio as a common synaptic trait in rat and primate models of LIDs as well as in dyskinetic PD patients; and (ii) validating the potential therapeutic effect of a cell-permeable peptide (CPP) interfering with GluN2A synaptic localization on the dyskinetic behavior of these experimental models of LIDs. Here we demonstrate an altered ratio of synaptic GluN2A/GluN2B-containing NMDA receptors in the striatum of levodopa-treated dyskinetic rats and monkeys as well as in post-mortem tissue from dyskinetic PD patients. The modulation of synaptic NMDA receptor composition by a cell-permeable peptide interfering with GluN2A subunit interaction with the scaffolding protein postsynaptic density protein 95 (PSD-95) leads to a reduction in the dyskinetic motor behavior in the two animal models of LIDs. Our results indicate that targeting synaptic NMDA receptor subunit composition may represent an intriguing therapeutic approach aimed at ameliorating levodopa motor side effects.

24 February 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JCJill R. Crittenden
Jill R. Crittenden
ICIppolita Cantuti-Castelvetri
Ippolita Cantuti-Castelvetri
ESEsen Saka
Esen Saka
CKChristine E. Keller-McGandy
Christine E. Keller-McGandy
LHLedia F. Hernandez
Ledia F. Hernandez
AGAnn M. Graybiel
Ann M. Graybiel
Voluntary movement difficulties in Parkinson's disease are initially relieved by l -DOPA therapy, but with disease progression, the repeated l -DOPA treatments can produce debilitating motor abnormalities known as l -DOPA-induced dyskinesias. We show here that 2 striatum-enriched regulators of the Ras/Rap/ERK MAP kinase signal transduction cascade, matrix-enriched CalDAG-GEFI and striosome-enriched CalDAG-GEFII (also known as RasGRP), are strongly and inversely dysregulated in proportion to the severity of abnormal movements induced by l -DOPA in a rat model of parkinsonism. In the dopamine-depleted striatum, the l -DOPA treatments produce down-regulation of CalDAG-GEFI and up-regulation of CalDAG-GEFII mRNAs and proteins, and quantification of the mRNA levels shows that these changes are closely correlated with the severity of the dyskinesias. As these CalDAG-GEFs control ERK cascades, which are implicated in l -DOPA-induced dyskinesias, and have differential compartmental expression patterns in the striatum, we suggest that they may be key molecules involved in the expression of the dyskinesias. They thus represent promising new therapeutic targets for limiting the motor complications induced by l -DOPA therapy.

3 March 2017 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
LHLedia F. Hernández
Ledia F. Hernández
ICIvan Castela
Ivan Castela
IRIrene Ruiz‐DeDiego
Irene Ruiz‐DeDiego
JOJose A. Obeso
Jose A. Obeso
RMRosario Moratalla
Rosario Moratalla